ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1672

Facilitating the Medication Decision-Making process—What Do Patients with Lupus Nephritis Say?

Ricahrd Shewchuk1, Haiyan Qu2, W. Winn Chatham2, Jinoos Yazdany3, Maria Dall'era4 and Jasvinder A. Singh5, 1University fo Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5University of Alabama and VA Medical Center, Birmingham, AL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: African-Americans, Hispanic patients, Lupus nephritis, medical management and qualitative

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Low medication adherence in lupus nephritis puts patients at risk for poor outcomes, but to our knowledge, relatively little is known about what patients perceive as facilitative factors in medication decisional processes. Our objective was to comprehensively identify factors that racial/ethnic minority patients with lupus perceive as facilitating decisions to take their lupus medications as prescribed.

Methods: We conducted 8 Nominal Group Technique (NGT) meetings with patients with lupus nephritis who received treatment from lupus clinics at University of Alabama at Birmingham (UAB) and University of California at San Francisco (UCSF). Patient perceptions of facilitators influencing the medication decision-making outcome were generated by asking the following question: “What sorts of things make it easier for people to decide to take the medications that doctors prescribe for treating their lupus kidney disease?” Patients in each NGT meeting prioritized a subset of facilitative factors in terms of importance using a voting procedure.  To obtain an aggregated result, responses with the same or very similar wording generated by different groups were combined and the voting totals for all prioritized responses were summed across groups.

Results: 52 patients with lupus nephritis participated in 8 NGT meetings: 27 African Americans (4 nominal groups), 13 Hispanic (2 nominal groups) and 12 Caucasian (2 nominal groups). Mean age was 40.6 years (SD=13.3), disease duration was 11.8 years (SD=8.3), 34.6% had education level of college or greater, 55.8% needed help with reading health materials, indicating low health literacy. The participants generated 281 responses (range=26-42 responses/meeting). 36% of all responses were endorsed across all groups by patients as relatively more important than others in facilitating decisions to take prescribed medications (range=31-52% of endorsed facilitators/total). More variation in the level of agreement about the importance of specific facilitators was observed with African American patients (range 31-52%) than with Caucasian (32-37%) and Hispanic patients (31-34%).  Overall, participants allocated about 57% of the available votes from all groups as an endorsement of perceived importance to 8 facilitators that can be briefly summarized as: demonstrated efficacy, longevity expectations, symptom relief, expectations for living a more normal life, family, cost and affordability, awareness of potential risks and benefits, and minimal side effects.

Conclusion: A general consistency of factors perceived to facilitate medication decision making by lupus nephritis patients was noted across ethnic/racial groups. Patient-identified facilitators of lupus medication adherence can inform the design of effective educational materials for patients with lupus nephritis.


Disclosure:

R. Shewchuk,
None;

H. Qu,
None;

W. W. Chatham,
None;

J. Yazdany,
None;

M. Dall’era,
None;

J. A. Singh,

takeda, savient,

2,

takeda, savient, regeneron, allergan,

5.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facilitating-the-medication-decision-making-process-what-do-patients-with-lupus-nephritis-say/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.